Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03813160 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Phase 3 study, sponsored by Corbus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
NCT03813160 is a Phase 3 study that has completed, run by Corbus Pharmaceuticals. The registered enrollment target is 176 participants.
The verdict
NCT03813160, a Phase 3 study, has completed, sponsored by Corbus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
Study Summary
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Approximately 150 subjects will be enrolled in this study at about 60 sites in North America, Europe, and Asia. The planned duration of double-blind treatment with study drug is up to 52 weeks.
Interventions
- DRUG Placebo
- DRUG Lenabasum 20 mg
- DRUG Lenabasum 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2018-12-17 |
| Est. Completion | 2021-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03813160
The ClinicalTrials.gov registry entry for NCT03813160 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corbus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03813160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03813160 about?
NCT03813160 is a clinical study titled "Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis". This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Approximately 150 subjects will be enrolled in this study at about 60 sites in North America, Europe, and Asia. The planned duration ...
What is the current status of trial NCT03813160?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2018-12-17. Estimated completion is 2021-10-05.
What interventions are being tested in trial NCT03813160?
The interventions under investigation include: Placebo (DRUG), Lenabasum 20 mg (DRUG), Lenabasum 5 mg (DRUG).
Who is sponsoring clinical trial NCT03813160?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.